Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 4 Years in the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. (2024). SKIN The Journal of Cutaneous Medicine, 8(4), s407. https://doi.org/10.25251/skin.8.supp.407